Literature DB >> 7853411

Should anticancer drug doses be adjusted in the obese patient?

S D Baker, L B Grochow, R C Donehower.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7853411     DOI： 10.1093/jnci/87.5.333

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  8 in total

1.  Availability and utility of body mass index for population-based cancer surveillance.

Authors:  Theresa H M Keegan; Gem M Le; Laura A McClure; Sally L Glaser
Journal:  Cancer Causes Control       Date:  2007-10-18       Impact factor: 2.506

Review 2.  Clinical pharmacology in the adolescent oncology patient.

Authors:  Gareth J Veal; Christine M Hartford; Clinton F Stewart
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

3.  The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436).

Authors:  Vicki A Morrison; Linda McCall; Hyman B Muss; Aminah Jatoi; Harvey J Cohen; Constance T Cirrincione; Jennifer A Ligibel; Jacqueline M Lafky; Arti Hurria
Journal:  J Geriatr Oncol       Date:  2017-12-08       Impact factor: 3.599

Review 4.  Drug dosing and monitoring in obese patients undergoing allogenic stem cell transplantation.

Authors:  Claudia Langebrake; Friederike Bernhardt; Michael Baehr; Nicolaus Kröger; Axel R Zander
Journal:  Int J Clin Pharm       Date:  2011-09-29

Review 5.  Practical treatment guide for dose individualisation in cancer chemotherapy.

Authors:  P Canal; E Chatelut; S Guichard
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

6.  Breast cancer adjuvant chemotherapy dosing in obese patients: dissemination of information from clinical trials to clinical practice.

Authors:  Christopher G Greenman; Christina H Jagielski; Jennifer J Griggs
Journal:  Cancer       Date:  2008-05-15       Impact factor: 6.860

7.  Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens.

Authors:  Raafi Ali; Vickie E Baracos; Michael B Sawyer; Laurent Bianchi; Sarah Roberts; Eric Assenat; Caroline Mollevi; Pierre Senesse
Journal:  Cancer Med       Date:  2016-01-27       Impact factor: 4.452

8.  Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer.

Authors:  C Kloft; W Siegert; U Jaehde
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.